We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

41 hedge funds and large institutions have $1.84M invested in VYNE Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 41 → 41 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.01% less ownership

Funds ownership: 0.8% → 0.79% (-0.01%)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

43% less capital invested

Capital invested by funds: $3.25M → $1.84M (-$1.41M)

Holders
41
Holders Change
–
Holders Change %
0%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$30.8K
2
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$24.8K
3
Jane Street
Jane Street
New York
+$18K
4
Millennium Management
Millennium Management
New York
+$12.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$8.87K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$53.7K
2
TSS
Two Sigma Securities
New York
-$50K
3
Citigroup
Citigroup
New York
-$16K
4
RC
RegentAtlantic Capital
New Jersey
-$10K
5
Ameriprise
Ameriprise
Minnesota
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
DA
1
DSC Advisors
Illinois
$596K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$368K -$53.7K -8,391 -8%
Renaissance Technologies
3
Renaissance Technologies
New York
$207K -$3.75K -585 -1%
BlackRock
4
BlackRock
New York
$197K -$819 -128 -0.3%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$100K – – –
State Street
6
State Street
Massachusetts
$47K – – –
Millennium Management
7
Millennium Management
New York
$44K +$12.2K +1,906 +21%
TCM
8
Tekla Capital Management
Massachusetts
$30K – – –
Mackenzie Financial
9
Mackenzie Financial
Ontario, Canada
$30K +$24.8K +3,871 +107%
CAN
10
Cetera Advisor Networks
California
$26K – – –
Franklin Resources
11
Franklin Resources
California
$21K – – –
Northern Trust
12
Northern Trust
Illinois
$20K – – –
Bank of America
13
Bank of America
North Carolina
$20K +$448 +70 +1%
Citadel Advisors
14
Citadel Advisors
Florida
$19K +$30.8K +4,812 New
BPA
15
Beacon Pointe Advisors
California
$17K – – –
VF
16
Virtu Financial
New York
$14K -$1.2K -187 -5%
SCA
17
STALEY CAPITAL ADVISERS
Pennsylvania
$14K – – –
Thrivent Financial for Lutherans
18
Thrivent Financial for Lutherans
Minnesota
$12K – – –
Jane Street
19
Jane Street
New York
$11K +$18K +2,813 New
DAM
20
Deltec Asset Management
New York
$7K – – –
Morgan Stanley
21
Morgan Stanley
New York
$6K -$6.56K -1,025 -44%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$6K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$6K +$5.44K +850 +128%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$6K +$8.87K +1,385 New
CL
25
CSS LLC
Illinois
$5K -$403 -63 -4%
1
2

VYNE Hedge Fund Activity: Q3 2022 in Review

41 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2022, worth a combined $1.84M — down 43% from $3.25M a quarter earlier.

Fund positioning in VYNE was balanced in Q3 2022: 6 funds opened new positions, 6 closed out, 6 added to existing stakes and 8 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $30.8K. The largest seller was Vanguard Group, cutting an estimated $53.7K.

  • 41 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $1.84M of VYNE Therapeutics stock for Q3 2022, down 43% quarter-over-quarter.
  • 6 funds opened new VYNE Therapeutics positions in Q3 2022 and 6 closed out, a net change of 0 holders.
  • The largest VYNE Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $30.8K added.
  • The largest VYNE Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $53.7K sold.

Based on aggregated 13F filings for Q3 2022.